Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Telpegfilgrastim - Xiamen Amoytop Biotech

Next Previous
Drug Profile

Telpegfilgrastim - Xiamen Amoytop Biotech

Alternative Names: Pegneugen; Telpegfilgrastim injection - Xiamen Amoytop Biotech; Y-shaped branched pegylated filgrastim - Xiamen Amoytop Biotech; YPEG-filgrastim - Xiamen Amoytop Biotech; YPEG-rhG-CSF - Xiamen Amoytop Biotech

Latest Information Update: 13 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Xiamen Amoytop Biotech
  • Developer Sun Yat-Sen University; Xiamen Amoytop Biotech
  • Class Antihypertensives; Antineoplastics; Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Granulocyte colony stimulating factor replacements; Granulocyte colony-stimulating factor receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Chemotherapy induced febrile neutropenia
  • Phase I Preeclampsia

Most Recent Events

  • 08 May 2025 Xiamen Amoytop Biotech and complets a phase Ia trial for Preeclampsia (In volunteers) in China (SC, Injection) (NCT06893796)
  • 15 Apr 2025 Xiamen Amoytop Biotech plans a phase-II trial for Chemotherapy induced febrile neutropenia (In adults, In adolescent, In children) in China (SC), (NCT06926751)
  • 06 Apr 2025 Xiamen Amoytop Biotech initiates enrolment in a phase Ia trial in Preeclampsia (In Volunteers) in China (SC) (NCT06924385)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top